DVA News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

DV

Mkt Cap

$11.95B

Volume

411.83K

Next Earnings

November 4th

Loading chart

DV

DVADaVita Inc.

DVA

Pay with—

Available Balance0.00

DV

Mkt Cap

$12.07B

Volume

411.82K

Next Earnings

November 4th

Chart Financials Earnings News About Insider Filings

DaVita HealthCare (DVA) Stock Moves -1.01%: What You Should KnowDaVita HealthCare (DVA) closed at $187.25, down 1.01% in the latest session but outperforming the S&P 500's 1.09% decline. The kidney dialysis provider is forecasted to report EPS of $3.78 (up 50.6% YoY) with revenue expected at $3.53 billion (up 3.23% YoY). Trading at a Forward P/E of 12.98 versus the industry average of 20.96, DVA appears undervalued. The stock holds a Zacks Rank #3 (Hold) with a PEG ratio of 0.49, significantly below the industry average of 1.82.Zacks Investment Research · Oct 16, 2026

Why DaVita HealthCare (DVA) Outpaced the Stock Market TodayDaVita HealthCare (DVA) closed at $179.25, up 1.26% and outperforming the S&P 500. The kidney dialysis provider is projected to report 50.6% EPS growth and 3.23% revenue growth in the upcoming quarter, with full-year estimates showing 35.16% earnings growth. Trading at a Forward P/E of 12.15 (below industry average of 20.06) and a PEG ratio of 0.46, DVA holds a Zacks Rank #3 (Hold) rating.Zacks Investment Research · Oct 9, 2026

Here's Why You Should Retain DaVita Stock in Your Portfolio for NowDaVita (DVA) has rallied 55.8% year-to-date, driven by strong Integrated Kidney Care (IKC) platform growth, improving treatment volumes, and technology investments. The company beat Q2 expectations by $40 million in adjusted operating income and raised full-year guidance. However, persistent headwinds include declining revenue per treatment due to commercial-mix pressure (estimated $70 million impact in 2027), elevated G&A costs limiting operating leverage, and limited acquisition opportunities in a consolidated market.Zacks Investment Research · Oct 9, 2026

Strength Seen in Option Care (OPCH): Can Its 32.7% Jump Turn into More Strength?Option Care Health (OPCH) surged 32.7% following the announcement of its acquisition by CD&R and McKesson for $32.05 per share in cash, representing a 37% premium to the previous closing price. The $5.8 billion enterprise value deal underscores the strategic appeal of OPCH's home and alternate-site infusion care platform. However, with unchanged earnings estimate revisions over the past 30 days, analysts caution that sustained momentum may depend on future estimate trends.Zacks Investment Research · Oct 7, 2026

DaVita HealthCare (DVA) Laps the Stock Market: Here's WhyDaVita HealthCare (DVA) closed at $178.69, up 1.33%, outperforming the S&P 500's 0.73% gain. The kidney dialysis provider is projected to report earnings of $3.78 per share with 50.6% year-over-year growth. The stock trades at a Forward P/E of 12.1, below the industry average of 19.68, and holds a Zacks Rank of #3 (Hold) with a PEG ratio of 0.46, indicating potential value.Zacks Investment Research · Oct 2, 2026

Can Fresenius Medical's 5008X Rollout Drive the Next Growth Phase?Fresenius Medical Care is scaling up its 5008X CAREsystem rollout, converting 227 U.S. clinics to the new technology by July 2026, representing 10% of its machine base. The company has performed over 600,000 treatments including 100,000+ high-volume hemodiafiltration treatments, showing clinical promise with 40% fewer muscle cramps. However, near-term headwinds include weak U.S. treatment volume growth (-0.9%), TDAPA reimbursement pressure (€50 million drag expected), and significant rollout implementation costs.Zacks Investment Research · Sep 3, 2026

Zacks Industry Outlook Highlights DaVita, LifeStance Health, Option Care Health, and Aveanna HealthcareThe Outpatient & Home Healthcare industry is experiencing rapid growth driven by digital transformation, an aging population, and cost-effectiveness advantages. The industry has a Zacks Industry Rank #52 (top 21%) with a forward P/E of 19.1X. Four key stocks are highlighted: LifeStance Health (Rank #2) with 19.7% revenue growth, Option Care Health (Rank #2) with 1.9% revenue growth, Aveanna Healthcare (Rank #2) with 10.6% revenue growth, and DaVita (Rank #3) with 4.7% revenue growth.Zacks Investment Research · Aug 31, 2026

Warren Buffett and Greg Abel Quietly Hold a Bigger Percentage of This Company Than Any Other in Berkshire's Portfolio (Hint: It's Not Apple or American Express)Berkshire Hathaway holds nearly 45% of DaVita, a kidney dialysis healthcare company, representing its largest proportional equity stake—larger than Apple or American Express. Despite recent modest sell-offs in 2025, DaVita has surged over 56% year-to-date, driven by strong Q1 earnings that beat analyst expectations. The company offers consistent profitability, revenue growth, and an attractive forward P/E ratio of just over 12.The Motley Fool · Aug 27, 2026

Everyone Is Watching Greg Abel. But Another Berkshire Hathaway Stock Picker Is Quietly Winning in 2026.While Greg Abel has taken over as CEO of Berkshire Hathaway, investment manager Ted Weschler continues to play a significant role in portfolio decisions. Two stocks personally selected by Weschler—DaVita and Sirius XM—have performed exceptionally well in 2026, with DaVita up over 102% and Sirius XM up over 50% year-to-date. This suggests Berkshire is maintaining its traditional value investing approach alongside Abel's newer pivot toward technology stocks.The Motley Fool · Jul 9, 2026

1 Sector Warren Buffett and Greg Abel Are Largely Ignoring -- and Why Investors Shouldn'tWarren Buffett and Greg Abel's Berkshire Hathaway portfolio is notably absent from the healthcare sector, holding only DaVita and recently exiting UnitedHealth Group. The article argues investors should consider healthcare independently, as it offers opportunities across multiple investment styles—from high-growth pharma/biotech plays like Eli Lilly to dividend-paying stalwarts like Johnson & Johnson and Abbott Laboratories that provide steady earnings and income.The Motley Fool · Jun 3, 2026

to start trading

DV

DVADaVita Inc.

DVA

Pay with—

Available Balance0.00

Your PositionYou don't own any DVA yet.

Related Tickers

Earnings